• Naltrexone + Bupropion is FDA approved for chronic weight management. (FDA, 2014)
• Common side effects of Contrave™ include dry mouth, constipation, headaches, vomiting, and dizziness.
• The minimum FDA requirement for placebo-corrected weight loss is 5%. Though contrave met this minimum requirement, there were initial concerns about CV safety.
• Relative contraindication in uncontrolled HTN, seizure disorder, chronic opioid use, bulimia, or anorexia nervosa.
Reference
Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Aug 21;376(9741):594. Erratum in: Lancet. 2010 Oct 23;376(9750):1392.